Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Indian Journal of Forensic Medicine & Toxicology
Saad Dakhil F. Daraji
Unknown Affiliation
Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Role of Serum Levels of Thymidine Kinase 1 in Diagnosis and Differentiating of Prostatic Tumor Lara Balasim Al-Dahy; Basil O. Mohammed; Saad Dakhil F. Daraji; Mazin M. Farhan
Indian Journal of Forensic Medicine & Toxicology Vol. 15 No. 4 (2021): Indian Journal of Forensic Medicine & Toxicology
Publisher : Institute of Medico-legal Publications Pvt Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37506/ijfmt.v15i4.16939

Abstract

Background: Both benign prostatic (BPH) and prostate (Pca) hyperplasia include prostate enlargement. Thedistinction between benign prostatic hyperplasia and prostate cancer is a major challenge, since the prostaticspecific antigen (PSA) cannot be considered a reliable predictor of prostate cancer. Aims: Efficiency ofserum thymidine kinase 1 and PSA-related biomarkers in prostate tumor, BPH and PCa diagnosis anddifferentiation, especially when serum PSA is in the gray (4-10 ng/ml) region and in the pronostic of thesepatients after surgical therapy. Subjects and Methods: A case control and cross-sectional review. Therewere 110 elderly patients (45-81 years) and 45 controle. Serum experiments involved the use of ELISAtechnologies to measure tPSA, fPSA, and TK1. Result: In comparison to both of the BPH and controls, themean (±S D) of serum tPSA and fPSA in Pca were significantly improved (all p =0,001) while the meanvalue of f PCa in comparison with BPH and control was dramatically decreased (p = 0,001) for fPSA/tPSA.There was no difference between BPH and controls in these parameters. In both of the Pca and Controls(P<0.001) the mean TC1 was slightly higher (P<0.001). This serum TK1 has the most receptive and specificdiagnostic and differentiating potency in the gray zone of tPSA (4-10 ng/ml), which has tPSA in the grayzone with AUC=1 in the 924 pg/ml cut-off zone.Conclusion: Serum level of TK1 was superior of tPSA in diagnosis of prostate tumor and differentiatingbetween BPH and PCa.
Dihydrotestosterone and Free/Total Prostatic Specific Antigen Ratio in Diagnosis and Prognosis of Prostatic Disease Lara Balasim Al-Dahy; Basil O. Mohammed; Saad Dakhil F. Daraji; Mazin M. Farhan
Indian Journal of Forensic Medicine & Toxicology Vol. 15 No. 3 (2021): Indian Journal of Forensic Medicine & Toxicology
Publisher : Institute of Medico-legal Publications Pvt Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37506/ijfmt.v15i3.15692

Abstract

Background: Both benign prostatic hyperplasia (BPH) and prostate cancer (Pca) include prostate enlargement. The second most common cancer among men worldwide is prostate cancer. It has been documented that by the time they reach their 60s, most men will experience benign prostatic hyperplasia. There is a real difficulty differentiating between benign prostatic hyperplasia and prostate cancer, the prostatic specific antigen (PSA) is not used as a reliable marker of prostate cancer. It is a specific biomarker measure specific to prostate tissues and not prostate cancer. Aims In the analysis of the gray zone of tPSA (4-10 ng/ml), add these biochemical markers and differentiate the root cause of prostate tumor in order to minimize painful and intrusive prostate biopsy. Materials and Methods: A cross-sectional and case control study. It included 110 patients ages range (45-81 years) with benign prostatic hyperplasia (n=55) and prostate cancer (n=55). Forty -five apparently healthy subjects were also included as controls. Peripheral blood samples from controls and patients were collected before obtaining a prostatic biopsy from patients. Serum samples were used for measurements of total Prostate Specific Antigen (tPSA), Free Prostate Specific Antigen (fPSA), and Dihydrotestosterone (DHT) by using ELISA technique. Result: Mean (±SD) serum tPSA and fPSA values for Pca were substantially improved compared to both BPH and control (p=0.001 for all), while mean fPSA/tPSA values for PCa were significantly decreased compared to BPH and control values (p=0.001). In PCa, the mean +SD value of the DHT ratios was significantly lower than in each BHP, and controls (P<0.001) were significantly lower in PCa than in each BHP and regulation (P<0.001). The mean DHT values for BPH were significantly higher as compared to control values (p< 0.001). Conclusion: The level of serum tPSA is 4.2 ng/ml for prostate tumor screening, while 10.1 ng/ml for PCa and BPH differentiation.
Co-Authors Basil O. Mohammed Lara Balasim Al-Dahy Mazin M. Farhan